XSHE
300584
Market cap594mUSD
Jul 09, Last price
33.60CNY
1D
-1.35%
1Q
-23.43%
IPO
186.36%
Name
Nanjing Hicin Pharmaceutical Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nanjing Hicin Pharmaceutical Co., Ltd. (NHPC), established in 2003 and headquartered in Nanjing, China, operates as a comprehensive enterprise specializing in the research, development, production, marketing, and distribution of pharmaceutical preparations and synthetic chemicals within China. The company boasts a diverse product portfolio, addressing various therapeutic areas such as antivirals, antibiotics, endocrine regulators, gastrointestinal treatments, orthopedic medications, cardiovascular and cerebrovascular drugs, and immunomodulatory agents. Beyond its core pharmaceutical activities, NHPC also provides technology transfer services. On an international scale, Nanjing Hicin Pharmaceutical Co., Ltd. is a supplier of Active Pharmaceutical Ingredients (APIs). Its export offerings specifically include injectable forms of omeprazole sodium and cefepime hydrochloride, along with lansoprazole tablets, which reach markets across South Asia, South America, and Europe.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||